64x Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $59M

Overview

64x Bio is a private, platform-based biotech company founded in 2020 and headquartered in San Francisco. The company's mission is to solve the critical manufacturing scalability challenges facing advanced therapies like gene and cell therapies through its proprietary VectorSelect™ platform. This platform combines high-throughput genetic screening and computational biology to systematically engineer production cell lines for higher yield and efficiency. 64x Bio operates a B2B business model, offering both licensed products (like its AAV Apex Suite) and custom optimization services to biopharma partners and CDMOs.

Cell TherapyGene TherapySynthetic Biology

Technology Platform

VectorSelect™ platform: an integrated system using massively parallelized genetic screens, computational biology (Cell Map), and process optimization to engineer high-yield production cell lines for biologics, viral vectors, and advanced therapies.

Funding History

2

Total raised:$59M

Series A$55MLightspeed Venture PartnersJan 15, 2023

Seed$4MLightspeed Venture PartnersJun 15, 2021

Opportunities

The massive and growing cell and gene therapy market is severely constrained by manufacturing limitations, creating a urgent need for yield-enhancing technologies.

64x Bio's platform-agnostic approach allows it to address bottlenecks across AAV, lentivirus, and traditional biologics, giving it a large total addressable market.

Successful partnerships could position it as a critical enabler and standard-setter in advanced therapy manufacturing.

Risk Factors

Key risks include the technical challenge of consistently delivering generalized yield improvements, slow adoption by partners due to the regulatory burden of changing manufacturing processes, and significant competition from both large tools companies and other biotech startups.

As a private, pre-commercial company, it also faces financial runway risk.

Competitive Landscape

64x Bio competes in the cell line engineering and bioprocess optimization space. Competitors include large life science tools companies (e.g., Thermo Fisher, Sartorius) with media and process solutions, and other synthetic biology startups focused on strain/cell line engineering. Its differentiation lies in the scale of its parallel screening and its integrated computational Cell Map designed specifically for therapeutic production.

More companies in Biologics / Biosimilars →More companies in United States →